The Trump administration continues to advance key priorities outlined in its executive orders, including imposing tariffs on trade partners. In July, President Trump released letters to U.S. trade partners outlining intended tariffs effective August 1, 2025, with implementation beginning August 7, 2025. These rates remain fluid as negotiations continue with impacted countries.
While initial proposals included pharmaceutical tariffs as high as 250%, recent negotiations between the United States and the European Union resulted in a significant reduction, limiting pharmaceutical tariffs to 15%. However, future trade agreements and tariff policies remain uncertain.
The focus of the tariff policy is to safeguard domestic industries and penalize trade partners. The impact remains polarizing, with concerns about efficacy and consumer burden. Critics argue that domestic entities may raise prices or shift to less efficient production models due to global trade dependencies.
Pharmaceutical impact
- Supply chains reliant on international trade may face disruptions, leading to higher drug prices and potential shortages.
- Generic drug costs may rise, as many ingredients are imported from China and India.
- Manufacturers may cease production of certain generics if tariffs reduce margins, affecting availability.
- Expanding U.S. drug manufacturing could strengthen national security but will take years to realize.
Patient considerations
- Higher out-of-pocket costs may reduce medication adherence, leading to poorer health outcomes.
- Drug shortages may force providers to use alternative treatments that are less effective, less safe, or more expensive.
- Maintaining a 90-day supply, via local or mail-order pharmacies, is a key strategy for continuity of care.
- Patients should understand pharmacy-wholesaler relationships, as access may vary between locations. Planning ahead, especially for generics, is essential.
Staying ahead of supply and pricing volatility
As tariff policies evolve, the healthcare industry faces potential disruptions in cost, access and care quality. Employers, providers and patients should stay informed and proactive by monitoring supply chains, preparing for shortages and supporting strategies that ensure continuity of care. While long term domestic manufacturing may offer stability, short-term planning and communication will be critical to navigating this shifting landscape.
